These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 9169309

  • 1. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
    Berzewski H, Van Moffaert M, Gagiano CA.
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S37-47; discussion S71-3. PubMed ID: 9169309
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M.
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J, Möller HJ, Burrows GD, Montenegro RM.
    Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reboxetine: a review of antidepressant tolerability.
    Mucci M.
    J Psychopharmacol; 1997 Mar; 11(4 Suppl):S33-7. PubMed ID: 9438231
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.
    Carvalhal AS, de Abreu PB, Spode A, Correa J, Kapczinski F.
    J Clin Psychiatry; 2003 Apr; 64(4):421-4. PubMed ID: 12716244
    [Abstract] [Full Text] [Related]

  • 11. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.
    Versiani M, Amin M, Chouinard G.
    J Clin Psychopharmacol; 2000 Feb; 20(1):28-34. PubMed ID: 10653205
    [Abstract] [Full Text] [Related]

  • 12. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R.
    J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
    Seguí J, López-Muñoz F, Alamo C, Camarasa X, García-García P, Pardo A.
    J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.